source
- Truist sees biotech rebound as M&A hits $136B and XBI climbs 34% in H1Truist Securities says the biotech sector is regaining momentum after a prolonged post‑pandemic slowdown, driven by rising merger activity, returning venture capital and easing policy risks. The S…
- Bristol Myers Squibb pauses autoimmune CAR‑T trials after life‑threatening side effectsBristol Myers Squibb announced in early June that it is pausing its CAR‑T therapy trials targeting autoimmune diseases after the trials reported life‑threatening side effects. The company informed…